

HealthTech Innovation Days

October 5&6 2020 at the Peninsula Paris and virtually



Focus on Healthcare innovation *Interviews of :*



Fabrice Andre

Head of Research, Gustave Roussy Institute, Villejuif

Speaker at «Cellular therapy & gene therapy : where do we stand, what perspectives ?»

Link to the replay : <https://htid-paris.streameo.fr/E10.html>



Frederic Revah

CEO at Genethon

Speaker at «Cellular therapy & gene therapy : where do we stand, what perspectives ?»

Link to the replay : <https://htid-paris.streameo.fr/E10.html>



Dominique Costantini,

Chairman and Director of early development, OSE Immunotherapeutics

Speaker at «Winning together: Successful corporate, healthtech companies and academic collaborations»



Oliver Schacht,

PhD, Bio Deutschland President

Speaker at «Opportunities and challenges for Innovative Healthtech companies in Europe (Bio-Deutschland & France Biotech)»

Link to replay : <https://htid-paris.streameo.fr/L5.html>




Gérard Raymond,

President of France Assos Santé

Speaker at «Opportunities in setting stronger relationship between health industry & patient association»

Link to replay : <https://htid-paris.streameo.fr/L6.html>



Cédric Moreau,

Partner at Sofinnova Partners

Speaker at «Why & How setting an efficient corporate governance in innovative firms to support growth ?»

Link to replay : <https://htid-paris.streameo.fr/E4.html>



Serge Braun

Scientific Director at AFM Telethon

Speaker at «Manufacturing challenges and step forwards in new therapies»

Link to replay : <https://htid-paris.streameo.fr/E13.html>

HEALTHCARE INNOVATION : Assets



Cellular therapy & gene therapy: where do we stand, what perspectives?




Pr Fabrice Andre, Head of Research,
Gustave Roussy Institute, Villejuif

«And the last thing which I think sums up the whole debate is this slogan used by one of the speakers:
RECODE FOR LIFE.»

Frederic Revah, CEO, Genethon

«Gene therapy is living a thrilling period.»



We just had a very good session dedicated to gene therapy and cell therapy which cover a very wide area of diseases.

What conclusions can we draw from it?

From a scientific perspective we have seen that it is possible to replace genes, and this led to major advances and major improvements in some patients, mostly with very rare diseases.

Regarding cell therapy, its effectiveness is already demonstrated at least in the field of immune deficiencies and blood malignancies even if they are still problems mainly related to T cell persistence, secondary resistance and toxicity.

What are now the main issues that we must address in order to extend the development of these innovative approaches and to have a real societal impact?

The first, and it was debated among the speakers because there was no consensus on this point, concerns the optimal regulatory path to make these new therapies available. The problem here is that if we have to develop and register a new drug for each gene, **the number of genes to be replaced is far too high and it becomes unrealistic.** While we all agree that safety is a key issue and we cannot compromise on it, at the same time we need to find new regulatory approaches for these products to facilitate their development and accelerate their approval.

The second point raised **was the issue of scaling and manufacturing.** And here there was also no consensus on the solutions, but new technologies or improvements of existing technologies should make easier the manufacturing and expand patient access.

The third point is **the patient access to these innovative therapies.** There was a general consensus here that access is still very limited, more than it is for targeted therapies or antibodies. There is therefore a major problem of moving from a system where only a few patients will have access to the medication they need. Some of the speakers pointed out that there are new ways to invest, between philanthropy and pure profit. Perhaps that could be a way forward.

Finally, the fourth point concerned **the fact that these are biotechnology products.** They have to be improved step by step and each time we make a small step it is not possible to repeat the whole assessment again. It is therefore preferable to develop a series of improvements and evaluate the whole. Perhaps we should assess whether a product that includes many knock-out or knock-in genes improves the outcome, rather than assessing the value of each KI/KO gene.

We were also impressed by **the vitality and willingness of academic centers to create start-up.** We have found at least four good illustrations of how a university center can be at the origin of a successful start-up that will feed larger pharmaceutical companies. And this is extremely important for the university institution.

Finally, we discussed strategic decisions. **What are the criteria for deciding gene replacement?** Why replacing a gene instead of trying to design a drug? This question has arisen about the modulation of the epigenetics of the SUV39H1 protein, **why turn it off using cell therapy if it can be targeted by a drug?** Another question that could be a limitation to this approach concerns the modification of the immune response when we replace a gene. This is a real problem.

And the last thing which I think sums up the whole debate is this slogan used by one of the speakers: **RECODE FOR LIFE.**

Gene therapy is going through **thrilling times.**

We see numerous compounds reaching the market, both for **rare genetic diseases and for cancer indications.** And, as those products develop and as tens of products are at Phase 3 development stage, the challenge for the future is ensure sustainable **flow of drugs** reaching the market by addressing the **specific issues and challenges gene therapy faces.** Of course, success is strongly dependent upon excellent science, on excellent understanding of the molecular bases of the diseases we're addressing, but beyond this science and beyond this translational medicine, we really have to address some **key hurdles** that might be limiting factors in the future.

What are these key factors?

If we want to make these gene therapy products available for a large number of indications and a very large number of patients, **we certainly have to solve the question of Bio-production.**

Of course Bioproduction for gene therapy raises industrial and logistics issues such as for instance in ex vivo modalities as **CAR-T treatments.** But not only, for in vivo gene therapy modalities the quantities of virus that you have to produce is such that **existing capacities** will not be able to match the needs; even for rare genetic diseases such as Duchenne muscular dystrophy, which requires all muscles from the body to be transduced.

Here, you know, you have to keep in mind that whereas for a vaccine you need 10E6 viral particles per dose, for Duchenne muscular dystrophy, you need 10E16 viral particles per dose! Here you have to come up with **strong improvements, disruptive improvements in production process.**

You will not have the possibility of doing more with the same process, but you actually need to come up with **new and disruptive technologies, new approaches in bio-manufacturing.** And this is going to be a **key element** among the number of factors what will be required to also decrease the price per unit.

Then there's other elements that have to be worked out, improving efficiency of the vectors being **more efficient, better expression cassettes,** which also will contribute in decreasing the doses to be injected.

An additional key aspect for future development for gene therapy is really addressing **the possibility of reinjecting those products.** We are treating today patients only once with spectacular results

«Sanofi and HealthTech Innovation Days are both involved in improving patient access to health innovation. It was a pleasure to be here for the second year in a row.» **Sanofi**

Frederic Revah, Following interview

over several years. But, as the patients grow old they might need to be redosed and we will have to transform, what is today a one-shot treatment into a repeated treatment or maybe even a **chronic treatment**. And to achieve this we have to be able to overcome the immune response following injections and develop immune modulators, which will allow us to address this issue.

Our industry has to face **the question of pricing** in order to ensure wide patient access to these therapies. For the time being, gene therapy products are the most expensive treatments on the market. Can this be a sustainably the case? I don't think so. If we successfully cope the challenges I mentioned before I consider that we can bring those products to a **more accessible pharmaco-economic equation**.



Winning together: Successful corporate, healthtech companies and academic collaborations
Dominique Costantini, Chairman and Director of early development, OSE Immunotherapeutics



Building relationships with academic institutions is of major importance for Biotechs and collaboration takes place at different levels.

First of all, at **the clinical level**, because it is the beginning of any discussion. To understand what kind of unmet need we could solve with our product, we at OSE Immunotherapeutics have antibodies that targets immune checkpoints expressed in the myeloid lineage, the first meeting obviously had to be about **clinical orientation**.

But behind that, we have also implemented a **research approach with bioinformatic tools**, with artificial intelligence in order to anticipate and explore different levels of interest from the new targets on which we are working. This is the reason why we have **worked in depth with Leon Berard anticancer center**. Jean Yves Blay, director of the center, has a formidable team around him. It was a key element getting the whole team involved and allowing our colleagues to have in front of them people experienced in the field of immune escape.

To understand, if the target expression changes, and, this is very interesting, if we are not in the presence of something completely different in theory. But also to understand the clinical situation, what is our vision of this target and the type of modification to better understand the future. The last point is to understand **what rare cancers really are**. A certain **time** for development is very important and these **discussions** on rare cancers are also important to understand if the product could also benefit from this possibility of exploring rare cancers and thus accelerating its development, it is an key element to our operational and development processes.

So, what are really the main factors that drive the relationship and the success of the partnership? I think what is essential is **team collaboration**. This means that when we have Jean Yves Blay who is able to work with people who have a different vision, that is the key. And that vision is very important when we have a research team, a bioinformatics team, a translational team, and obviously a clinical team, then we have a continuum of people to who are dedicated. Then our team of researchers and clinicians can have access to a whole discussion process and not a step by step one. It is really a general process. And I think that is very important for the type of collaboration we have and which is exceptional!

« Invest Securities, part of All Invest group, is very proud to be the Investment bank partner of the HealthTech Innovation Days and to have contributed to the 2020 edition. Our support to the HealthTech Innovation Days is for us a major rendez-vous in all our contributions to the European Biotech and Medtech sector. All the healthcare team, including financial analysts, investment bankers and sales team will continue to support this great event and all the industry.» **Invest Securities**



HEALTHCARE INNOVATION : Opportunities



Opportunities and challenges for Innovative Healthtech companies in Europe (Bio-Deutschland & France Biotech)



Oliver Schacht

PhD, Bio Deutschland President

«FRANCE AND GERMANY BEING THE TWO EU KEY ENGINES, WE NEED TO COME TOGETHER TO DEVELOP OUR BIOTECH INDUSTRIES»

The recent HealthTech Innovation Days conference was an excellent platform to bring together entrepreneurs, investors and stakeholders in the European biotech industry.

I think one of the key aspects that emerged from the conversation was that there are very **common themes** on both sides of the River Rhine and frankly, all across Europe, in terms of the **key challenges that especially growth companies are facing**, after they've been started successfully, after they've made the first steps, when they're trying to really grow towards being able to run product development, clinical trials, scale up issues, even manufacturing capabilities.

And I think we've got some prime examples in the COVID-19 crisis that show how **we can successfully address these with providing the environment and the ecosystem for funding and financing**.

The theme that really emerged here is this **common interest**, while, of course, an entrepreneur or founder of a company will likely always look in his or her local environment and will start the company where (s)he is, where the weather is nice, where the food is good. We heard a lot about, you know, the south of France as one. **Opportunistic founders in Germany will likely start there, but I think the perspective to see me as a BIO Deutschland representative here was very, very welcome.** One, that is we've really got it right from the start. Look beyond national borders and think again, something that the current crisis is teaching us every day, that while, yes, you need to take local, even really small community individual measures, taking a purely national approach makes no sense at all. This is something that goes well beyond any single country. **It frankly goes well beyond Europe and it's a global challenge.**

But we as Europeans, in the biotech industry where **France and Germany are the two key engines of the European Union** as we know it today and as we'll have it after the Brexit, we need to come together to develop our biotech industries. **And offering a**



platform such as HealthTech Innovation Days to young and growing biotech companies in Germany to come to France, meet with investors, meet with stakeholders is definitively essential. And we've heard already some case studies and examples of even very early on joint ventures, collaborations.

I just read this morning in the news, that Evotech just got a major new financing from Qatar. But if you think about it, Evotech recently has also become a French-German company and in fact, historically, they've been German-UK. So, **they're really a global organization**, but with a very, very strong European and in fact French-German footprint. For me, this is a perfect example of getting the idea and planting that seed and then seeing what happens, whether it is **German investors investing in French companies, French investors investing in German companies, European or US investors investing in exciting startup companies where the technology is the best.** That, to me, is certainly a prime example of everything Europe should be in terms of collaboration, open platforms, communication, common goals and, getting creative and rolling up our sleeves and getting things done.

To me, that's really what Europe is all about. That's what our **biotech associations are all about.** And having these communication platforms is really a **great opportunity of bringing people together** that, when they meet, they are going to be creative with ideas will be floating around and who knows, maybe new ideas and new business opportunities from which collaborations may emerge.



«Dechert is proud to continue to support HealthTech Innovation Days and her founder and President Maryvonne Hiance on this strategic initiative for the development and success of France's biotech and medtech sectors. The second edition was perfectly orchestrated in unprecedented conditions. This renewed success demonstrates France's central role in Europe in life sciences especially innovative areas such as e-health or AI. Dechert's Paris specialized platform composed of +30 fully dedicated lawyers is pleased to be part of HealthTech Innovation Days's history.» Alain Decombe, Partner, Dechert

HEALTHCARE INNOVATION : Opportunities



Opportunities in setting stronger relationship between health industry & patient association

Gérard Raymond, President of **France Assos Santé**

«Why and how strengthening them?»



Today, we have reached a point where we need real political will, to truly enter **digital health** and include our **entire health system in these tools**. And it seems important to us that there be a real policy to say that this is the tool that will allow us to **transform our health system and it must be done quickly**.

The second thing is that, in effect, we are trying in this broad vision to no longer **compartmentalize public institutions, manufacturers, start-ups, etc.** Everyone in the legal framework can finally have their place, provided they respect the rules of the game. For example, on the use of anonymized health data by private actors, we must stop playing to scare ourselves. It is therefore necessary both for the State to show real political will but also for **the various players on the ground to play collectively**.

And the third point that seems important to me is that this common rule of the game is based on **transparency and respect** for all players and on an irreproachable and shared ethic.

These new challenges must bring people together rather than push them away and therefore it is for the patients that I represent important that there also be **these rules of co-construction of validation first and evaluation then**.



Opportunities in setting stronger relationship between health industry & patient association
health data highlights

Two observations were defined through this round table.

The first observation is that for the past 15 years, there has been **no collective progress in digital technology in France**. This leads to the following result: **Software everywhere with no common rules**.

It's Impossible to communicate on health data in a secure way. The government must take matters into its own hands. It must play its role in digital technology and health data management, it must define the rules and must also build a few **basic tools** to enable software to **communicate well with each other**.

The industrial ecosystem must be allowed to build **value-added digital solutions** based on the basic tools.

The second observation is that **citizens do not have their own health data**. We need to get the citizen into the «game». **They must own their data**. In order to solve this major problem, we hope that in 2022, **a digital health space will open up to every citizen**, allowing them to manage their own health data and the consents they wish to give.

Value base: **Digital healthcare must become a tool for the general public**. We must move forward collectively. Digital health is here to transform us towards the best. It can bring people together and create **a dialogue between patients and healthcare professionals**.

The conclusion of this round table ends with this important sentence to remember: **Digital technology at the service of the citizen**



"Pfizer is pleased to support the second edition of HealthTech Innovation Days, a true Innovation Hub in order to help the economic development of French and European healthtech companies to go further, faster, in the provision of innovative solutions for the benefit of patients." Pfizer



HEALTHCARE INNOVATION : Challenges

Why & How setting an efficient corporate governance in innovative firms to support growth ?

Cédric Moreau, Partner at **Sofinnova Partners**

«We are here to bring the right knowledge and guidance at the right time and help our companies attract the right people.»



Manufacturing challenges and step forwards in new therapies

Serge Braun, Scientific Director at **AFM Telethon**

«If we cannot produce enough, it will be useless and just a nice story, but a dead-end story»



"We were delighted to sponsor HealthTech Innovation Days conference in Paris for the second year in a row. Healthcare is global and goes beyond borders, and Europe is set to become the next hub for innovation, especially in healthcare over the next few years. This is why a meeting like HealthTech Innovation Days is so important for bringing together the most influential players in the industry. We look forward to the next edition! »

Sofinnova Partners

I am very happy to attend this second HealthTech Innovation Days event, which is for the first time a mix between **physical and virtual meetings**.

Healthcare is more than ever a **hot topic**. It is therefore the perfect timing for this conference, which was also **supported by President Emmanuel Macron**, who also emphasized the growing importance of the health tech industry in his opening remarks.

I just attended a panel on governance and it was very interesting to **share our perspective** as an investor and also to hear from human resources consultants, and the CEOs of the companies in our portfolio.

What is important from an investor's perspective is to be able to **support a company in all phases of growth**, to be able to anticipate and also coach the teams, and to ensure we have the right people, both at the management and board levels. Carrying out a Phase 3 clinical trial, marketing a product, or even entering into the clinic, **requires different sets of expertise**.

An early investor may not have the **same expertise** as a late stage investor. So, as a later-stage investor, we try to bring a **specific perspective** to leverage the potential of our companies. We need more of this in our ecosystem.

Perhaps in the past we have somewhat underestimated the importance of having **good corporate governance** in the companies in our portfolio. We are here to bring the **right knowledge and guidance** at the right time and help our companies attract the right people. So, we bring our **extensive network** and **our relationships** to help do this.

We are shareholders but we are **active shareholders**. Bringing in cash is important for sure. But we also leverage our network and help our businesses grow and take an **active role**. Just putting in the money and being a sleeping shoulder is absolutely not what we intend to do.

The point I made during this round table was **all about gene therapy**.

The question is: are production protocols and facilities enough around the globe to meet the needs? and the answer is **definitively, NO**.

There is a shortage of very robust production processes. This is a real threat for the whole field : we have a **nice technology**, but if we cannot produce enough, it will be useless, and just a nice story, but a dead-end story. And we know that there are some studies stating that, for instance, we would need something like fifteen hundreds of 2,000 liters fermenters bioreactors to produce the amounts that are needed for the current products or those that **will be on the market in the coming three to four years**.

The goal is to **increase production yields** by a factor of at least a hundred, if not a thousand in order to solve the issue. It's the **conjunction of different disciplines, different areas** as for instance, virology, because in most of the systems, the vectors used to transfer genes are products based on viruses, genetically modified viruses, and therefore **we need to improve the knowledge of those viruses**. It's also a question of cell biology, how the cells interact with viruses in order to make sure that the cells that are used to produce viruses produce larger amounts of viruses. **It's a question of purification technology. It's a question of in-process control**.

And we would then tackle another issue that is related to the **production one**. That is the cost of those products. Currently, gene therapy products **are very expensive**. For example, there is one product that is on the market for a rare disease, the spinal muscular atrophy, it's a one-shot administration but it costs two point one million dollars.

It's supposed to be the most expensive drug in the world and, in my estimation, is that half of its price is **explained by production costs**.

By improving production means, we should technically be able to reduce the costs and therefore the price of the drug. And because this may also impact patient access **it's another important aspect to take into account**.



PROGRAM 2020

<https://htid-paris.streameo.fr>



October 5th – Salon Etoile

12:50 – 2:00 PM : Grand Opening & Venture Centre of Excellence Programme Launch

Speakers:

Jan-Philipp Beck, CEO EIT Health
Jean-Marc Bourez, Managing Director of EIT Health France and Head of the VCoE
Thierry Breton, Commissioner at European Commission, Internal Market
Hubert Cottogni, Director and Head of Mandate Management
Alexandra Dublanche, Representative of Ile-De-France Region
Nicolas Dufourcq, CEO at Bpifrance
Maryvonne Hiance, President of HealthTech For Care
Franck Mouthon, President France Biotech and CEO of TheraNexus

2:00 – 3:00 PM : Keynote – Economic impact of Covid-19 on the healthtech ecosystem

Moderated by Christian Pierret, Former French Minister of Industry

Speakers :

Philippe Aghion, Professeur at Collège de France and at London School of Economics, member of Société économétrique and American Academy of Arts and Sciences.
Jan-Philipp Beck, CEO EIT Health
Thierry Breton, Commissioner at European Commission, Internal Market
Stewart Cole, Managing Director at l'Institut Pasteur

3:15 – 4:00 PM : Winning together : Successful corporate, healthtech companies and academic collaborations

Facilitator : Paul Barrett

Speakers :

1. Donna Armentano, Executive Director External R&D Innovation and Global Head Gene Therapy at Pfizer & Jean-Philippe Combal, PharmD, Ph.D co-founder & CEO at Vivet Therapeutics
2. Pr Jean-Yves Blay, Managing Director at Centre Léon Bérard and Président of Unicancer & Dominique Costantini, Chairman and Director of early development chez OSE Immunotherapeutics
3. Amaury Martin, Director, Technology transfer and Industrial partnerships, Institut Curie. & Luigi Ravagnan, Director, Strategic Collaborations, Global Medical, Bristol Myers Squibb

4:00 – 5:00 PM : Why & How setting an efficient corporate governance in innovative firms to support growth ?

Moderated by Lilian Stern, founder of Stern IR

Speakers :

Elsy Boglioli, CEO of Bio-up
Virginie Lléu, Founder and Executive director of L3S Partnership
Cédric Moreau, Partner at Sofinnova Partners
Nawal Ouzren, CEO of Sensorion

5:30 – 6:30 PM : Impact of the Covid-19 crises on financing opportunities and risks

Moderated by : Alain Pujol, Angels Santé Board member

Speakers :

Nissim Darvish, Partner Orbimed (Tel Aviv)
Marc Le Bozec, Fund Manager at Financières Arbevel
Camille Leca, Head of Listing France at Euronext
Philippe Monteyne, Partner @Fund+
Antoine Papiernik, Chairman & Managing Partner at Sofinnova Partners

6:30 – 7:00 PM : Value creation through smart partnerships. The biotech & pharma perspectives

Facilitator : Paul Barrett

Speakers :

Jean-Paul Kress, CEO at MorphoSys AG
Alban De La Sablière, SVP Global Head of Sanofi Partnering.

7:15 PM : Cocktail Reception

Agnès Pannier-Runacher, Minister Delegate to the Minister of the Economy, Finance and Recovery, in charge of Industry

PROGRAM 2020

<https://htid-paris.streameo.fr>



October 5th – Salon Lobby

2:00 – 2:30 PM : New EU regulations in the Medtech sector

Moderated by Alexandre Regniault, Lawyer at Simmons & Simmons

Speakers :

Marc Julien, Co-CEO Diabeloop

Lionel Dreux, President at GMED

Stéphane Piat, Managing Director at Carmat

Gary Slack, Senior Vice President Global Medical Devices at BSI.

2:30 – 3:00 PM : Medtech – Market Access

Moderated by Samuel Levy, Founding Partner at Lauxera Capital Partners

Speakers :

Graeme Brookes, CEO at Reapplix

Whitney Cypes, Vice President Global Marketing at Allurion Technologies

3:30 – 4:30 PM : VCoE : Innovating for Innovators

Speakers :

Jean-Marc Bourez, EIT Health France Managing Director and Head of the VCoE

Rémi Charrier, Global Head of Institutional Client Relationship, European Investment Fund

Stephan Christgau, Founding Partner, Eir Ventures

VP Value-based health & Innovation lead Europe, Amgen

Marc Julien, CEO, Diabeloop

Tomasz Kozlowski, Head of Mandate and Product Development, European Investment Fund

Patric Gresko, Head of Division – Innovation and Technology Investments, European Investment Fund

Henrik Matthies, Managing Director, Health Innovation Hub (HIH) Germany

Anne Osdoit, Partner, Sofinnova Partners (MDStart Fund)

Thomas Trailov, Director Strategy & Insights | World Business Line Healthcare, Air Liquide Santé International

4:30 – 5:00 PM : Keynote on entrepreneur & VC success (Corvidia Therapeutics learning experience)

Facilitator :Paul Barrett

Speakers :

Marc de Garidel, Chief Executive Officer at Corvidia Therapeutics

Graziano Seghezzi, Managing Partner at Sofinnova Partners

5:30 – 6:30 PM : Opportunities and challenges for Innovative healthtech companies in Europe (Bio-Deutschland & France Biotech)

Moderated by

Pierre Courteille, Chief Commercial Officer & Vice President Business Development at Abivax and VP at France Biotech

Oliver Schacht ,PhD, Bio Deutschland President

Speakers

Pierre Courteille, Chief Commercial Officer & Vice President Business Development at Abivax and VP at France Biotech

Jack Elands, CEO Emergence AG

Mondher Mahjoubi, CEO Innate Pharma

Oliver Schacht ,PhD, Bio Deutschland President

Jan Schmidt- Brand, CEO/CFO Heidelberg Pharma

6:30 – 7:15 PM : Opportunities in setting stronger relationship between, health industry & patient association

Speakers :

Dominique Pon, Minister Collaborator – Strategic Manager of the digital transformation in health & Managing Director of the

Clinique Pasteur in Toulouse

Gérard Raymond, President of France Assos Santé

PROGRAM 2020

<https://htid-paris.streameo.fr>



October 6th – Salon Etoile

8:30 – 11:30 AM : Cellular therapy & gene therapy: where do we stand, what perspectives?

Moderator : Christian Policard, Founding Partner at Biotech Développement Conseils

Chairmen : Pr Fabrice André , Head of Research, Gustave Roussy Institute, Villejuif & Frederic Revah, CEO, Genethon

Speakers :

Sebastian Amignorena, Research Director at Institut Curie, CNRS

Nathalie Cartier-Lacave, Director, NeuroGenCell Brain Lab and Spine Institute (ICM), Pitie-Salpetriere Hospital, Paris

Marina Cavazzana, Head of the Biotherapy Department at Necker Hospital and Imagine Institute

Patrick Henno, Co-founder of EMERCell

Mohamad Mohty, Head of the Hematology and Cellular Therapy Department at Saint-Antoine Hospital and University Pierre & Marie Curie

Jean-Antoine Ribeil, Medical Director in Medical Affairs Department at Bluebird Bio

11:30 – 12:15 PM : Renewed appetite for Medtech markets : VC/ Medtech duo

Moderated by André Michel Ballester

Speakers

Scott Bardo, Senior Healthcare Analyst at Berenberg Bank

Tim Haines, Chairman and Managing Partner at Abingworth

Sacha Loiseau, Venture Partner at Elaia

Bertin Nahum, Founder and President of Quantum Surgical

1:15 – 2:30 PM : Facing Covid-19 : challenges for Biotechs and Pharmas

Moderated by Eric Falcand, Global Head of Business Development and Licensing, Servier & Christian Policard, Founding Partner at Bio Développement Conseil (France)

Speakers :

Hugues Bultot, Co-founder and Chief Executive Officer Univercells

Christian Deleuze, Chairman of the Research & Innovation Commission at Leem

Rahim Fandi, Chief Medical Officer, Oxford Biotherapeutics

Laurent Levy, Co-founder and Chief Executive Officer Nanobiotix

Olivier Madec, Global Head of M&A and Venture Investments Servier

Frédéric Rothenburger, Managing Director at Lazard

Jacques Volckmann, Head R&D France, at Sanofi

2:45 – 3:45 PM : Manufacturing challenges and step forwards in new therapies

Facilitator : Paul Barrett

Speakers :

Serge Braun, Scientific Director at AFM Telethon

Frédéric Collet, Président at Leem (Les Entreprises du Médicament)

Richard Snyder, Vice President, Science and Technology Pharma Services, Viral Vector Services at ThermoFisher

Antoine Jourdan, Health Project Director at Direction Générale des Entreprises

4:15 – 5:30 PM : Amgen & EIT Health plenary session, Unleashing the true potential of AI in healthcare, together

Facilitator : Paul Barrett

Speakers :

Jean-Marc Bourez, Managing Director & Head of the VCoE, EIT Health France

David Dellamonica, Head Value Based Partnership & Digital innovation, DEEP AI Platform founder, Amgen Europe

Frederic Jean, Co-developer, Digital Medical Hub AP-HP

Henrik Matthies, Managing Director, Health Innovation Hub (HIH, Germany)

Philippe Menu, CMO SophiA Genetics

Karl Neuberger, Partner at Quantmetry

Arnaud Rosiers, CEO, Implicity

Stéphane Tholander, CEO & Co-Founder of Cibiltech

Stéphanie Trang, Managing Director of the AI for Health Initiative at Start-up Inside

Nicolas Villain, Director of the Research Department and AI HUB, Philips Healthcare

5:30 – 6:30 PM : Closing ceremony & Cocktail

PROGRAM 2020

<https://htid-paris.streameo.fr>



October 6th – Salon Lobby

8:45 – 9:45 AM : VCoE : EIF Market Insights (VCoE restricted plenary)

10:15 AM – 12:15 PM : VCoE : Shaping the Member Community Vision and Discussion (VCoE restricted plenary)

1:15 – 2:15 PM : Key Collaboration and Financing Issues during the Covid-19 Pandemic

Moderator

Paul Barrett

Speakers :

Anne-Charlotte Rivière, Partner, Paris at Dechert

David Schulman, Partner, Washington D.C. at Dechert

2:45 – 3:45 PM : Behavior of stakeholders in high volatility innovative markets like HealthTech

Moderated by

Pierre Courteille, Chief Commercial Officer & Vice President Business Development at Abivax and VP France Biotech

Speakers :

Professor Randall Kroszner, Deputy Dean for Executive Programs and Norman R. Bobins Professor of Economics at University of Chicago Booth

Professor Scott Meadow, Clinical Professor of Entrepreneurship at University of Chicago Booth

4:15 – 5:30 PM : Creating a New Culture of Innovation through Collaboration: the Bridging Academia with Industry Paradigm Shift

Moderated by

Gabriela Apiou, PhD, Director of Strategic Alliances at Mass General Research Institute and Assistant Professor of Dermatology at Harvard Medical School

& Robert Tepper, MD, Partner at Third Rock Ventures and Member of the Mass General Research Institute Advisory Council.

Speakers :

Patrick Fortune, PhD, Vice President, Market Sector at Mass General Brigham Innovation Office

Saptarsi Haldar, MD, Vice President of Research and Head of Cardometabolic Discovery at Amgen

Anthony Rosenzweig, MD, Chief of the Cardiology Division at Mass General Hospital

5:30 – 6:30 PM : Closing ceremony & Cocktail

Replays of the round tables : <https://htid-paris.streameo.fr>

About HealthTech For Care



The HealthTech For Care endowment fund, launched by France Biotech, is designed to support and promote access to care for all and, more specifically, to new medical technologies and drugs. The missions of the endowment fund are structured around three main areas: Supporting the development of the entire health ecosystem, accelerating the development of innovative therapies and treatments, and promoting better access to healthcare for patients in the French healthcare system and more widely throughout Europe. HealthTech For Care is administrated by Maryvonne Hiance, Elsy Boglioli, David Caumartin, Pierre Courteille, Eric Falcand, Marc Le Bozec, Cédric Moreau, Franck Mouthon, Christian Pierret and Christian Policard.

About EIT Health



Europe faces a turning point in health. An ageing population, the rising burden of chronic disease, and growing multi-morbidity are all placing pressure on health systems across Europe.

EIT Health is a vast, vibrant community of world leading health innovators backed by the European Union. Working across borders, our network connects approximately 150 world-class partner organisations, as well as entrepreneurs, start-ups and SMEs from the worlds of business, research, education and healthcare delivery. Our aim is to answer the biggest health challenges Europe faces and we believe that life changing innovation happens when these worlds meet and collaborate. That's why we call this the 'knowledge triangle'.

From our headquarters in Munich, six regional Innovation Hubs and InnoStars cluster, which brings together organisations from regions in which the overall pace of innovation is more moderate, we provide an ecosystem in which fresh thinking can thrive. Our Regional Innovation Scheme further expands our presence in 13 countries across Central, Eastern and Southern Europe. EIT Health also leads the development of the EIT Hub in Israel, which connects innovators across Europe to other key thriving ecosystems beyond the EU.

EIT Health is supported by the European Institute of Innovation and Technology (EIT), a body of the European Union. Our ambition is to enable people in Europe to live longer, healthier lives by transforming businesses and delivering new products and services that can progress healthcare in Europe and strengthen our economy.

EIT Health: Together for healthy lives in Europe.
For more information visit: www.eithealth.eu

About France Biotech



Founded in 1997, France Biotech is an independent association that brings together the country's leading innovative health companies and their expert partners. As a leader in health innovation and a privileged intermediary with public authorities in France and Europe, France Biotech's mission is to support the development of this industry in France, by improving the tax, legal, regulatory and managerial environment in which these companies operate and by advocating for their recognition as a leading-edge industry. France Biotech also aims to turn French innovative health technology companies into world leaders capable of designing and developing new innovations quickly and make them available and accessible to patients. France Biotech has founded and is developing the « HealthTech For Care » fund to strengthen the ability to federate, structure and encourage cooperation between the various stakeholders in the health tech sector in France and Europe. France Biotech is chaired since September 2019 by Franck Mouthon, CEO of Theranexus...

KEY NUMBERS 2020



2 Days in Paris and
in virtual
October 5&6, 2020



Hybrid event



Support
From Europe
and France



780
Participants



19
Conferences with
experts and KOLs



1000
Private meetings



15
Pharmaceutical
groups



300
Investors from all
around the world



150
HealthTech
Companies

Looking forward to seeing
you for HealthTech
Innovation Days 3 in
2021 !

Thanks to our partners



Platinum



Super Gold



Gold



Silver



Bronze



Social Media & Contacts



HealthTech Innovation Days
<https://www.linkedin.com/company/htid>



HealthTech Innovation Days
https://twitter.com/HTID_Paris



HealthTech For Care
<http://htfc-eu.com>



EIT Health is supported by the EIT, a body of the European Union

Estelle Metzger
Project Manager Junior
estelle.metzger@htfc-eu.com
+33 (0)6 38 03 80 60

Solene Goupy
Communication Manager
solene.goupy@htfc-eu.com
+33 (0)6 38 03 80 19

Nathalie Donne
Senior Advisor Manager
nathalie.donne@insead.eu
06 67 67 44 97